Phase II Trials in T-Cell Lymphoma: Romidepsin and Pegylated Liposomal Doxorubicin/Bexarotene


Phase II Trials in T-Cell Lymphoma: Romidepsin and Pegylated Liposomal Doxorubicin/Bexarotene
Slides from presentations at ASH 2011 and transcribed comments from a recent interview with Owen A O’Connor, MD, PhD (2/3/12) and from Steven M Horwitz, MD at a recent closed roundtable recording (3/9/12)

Coiffier B et al. Analysis of patients with common peripheral T-cell lymphoma subtypes from a Phase 2 study of romidepsin in relapsed or refractory peripheral T-cell lymphoma. Proc ASH 2011;Abstract 591.

Coiffier B et al. Results from a pivotal, open-label, Phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol 2012;30(6):631-6. Abstract

Straus DJ et al. Final results of Phase II trial of pegylated liposomal doxorubicin (PLD) followed by bexarotene (Bex) in advanced cutaneous T-cell lymphoma (CTCL). Proc ASH 2011;Abstract 882.

Dr Horwitz is Assistant Attending in the Division of Hematologic Oncology's Lymphoma Service at Memorial Sloan-Kettering Cancer Center in New York, New York.

Dr O'Connor is Professor of Medicine and Developmental Therapeutics and Director of the Center for Lymphoid Malignancies at Columbia University Medical Center in New York, New York.